Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will present at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2026. CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat at 8:40 AM ET, with management available for one-on-one investor meetings.
The live webcast is accessible via the company Events page and an archived replay will be available for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – RLMD
In the Mar 10 session, RLMD declined 7.67%, reflecting a notable negative market reaction. Argus tracked a peak move of +77.2% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Regulatory update | Positive | -4.6% | FDA written feedback supporting registrational Phase 3 design for NDV-01. |
| Dec 03 | Clinical data update | Positive | +0.5% | Phase 2 NDV-01 data with favorable safety and 92% complete response rate. |
| Nov 13 | Earnings and pipeline | Positive | +1.8% | Q3 2025 results plus strong NDV-01 data and Phase 3 pathway clarity. |
| Nov 07 | Earnings date notice | Neutral | +1.5% | Announcement of upcoming Q3 2025 results call and webcast logistics. |
| Nov 04 | Equity offering | Positive | +25.9% | Pricing of $100M underwritten stock and pre-funded warrant offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive, with the stock more often rising on favorable clinical, regulatory, and financing updates, but showing at least one notable divergence on a positive FDA alignment update.
Over the last several months, Relmada issued multiple clinically and financially significant updates. An offering on Nov 4, 2025 raised about $100M and coincided with a strong positive move. Subsequent Q3 2025 results on Nov 13 highlighted robust NDV‑01 data and extended cash runway into 2028. A Dec 3, 2025 presentation and a Jan 12, 2026 FDA alignment update advanced the NDV‑01 program toward Phase 3. Today’s conference appearance fits a pattern of active investor and scientific engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Leerink Partners Global Healthcare Conference being held in Miami, Florida, from March 8-11, 2026.
Leerink Partners Global Healthcare Conference Details
Format: Fireside Chat
Date Tuesday, March 10, 2026
Time: 8:40 AM ET
Webcast: Click Here
Management will also be available for one-one-one investor meetings during the conference. Please contact your Leerink Partners representative to schedule a meeting.
The webcast can also be accessed on the Events page the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar An archived replay will be available for 90 days following the conclusion of the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
